Background and Aims The time post-release from prison involves elevated mortality, especially overdose deaths.
INTRODUCTION
The ongoing overdose epidemic is a global public health crisis [1, 2] . Criminal justice populations are no exception, as they are typically drug-involved [3] and high mortality rates in individuals released from prison have been documented in several countries [4] [5] [6] [7] , with accidental drug overdose as the leading cause of death [8, 9] .
The concentration of overdose deaths within the early post-release period, compared to later time-periods, has been observed consistently for more than a decade [6, [9] [10] [11] [12] [13] [14] [15] . A meta-analysis, conducted by Merrall et al., of six studies (69 093 person-years and 1033 deaths) identified a three-to eightfold increased risk of drug-related death when comparing weeks 1 + 2 with weeks 3-12 [11] .
Most studies investigating overdose mortality following prison release are based on large-scale registry data: necessary in order to study rare outcomes (overdose mortality) within narrow time-frames (days and weeks following release). However, there are major challenges for such mortality studies [16] . The study of rare events, such as overdose deaths in a narrow period post-release, requires access to, and analysis of, data sets large enough to detect change over time. There are generally two main approaches; either to obtain data from the same setting over a long time-span [14, 15, 17] or the integration of data of a variety of study settings and differences in methodology (pooled data and meta-analysis) [11, 13] . The two approaches both have merit, but both also have inherent limitations. The inclusion of data over a long time-period needs to take into account temporal changes during the observation period and produce more than one single estimate. Conversely, pooled data sets need to take into account the differing drug-use patterns and treatment practices in order to make meaningful interpretations. For example, in the case of the Merrall et al. meta-analysis [11] , only six of the identified 18 studies were suitable for inclusion, due to heterogeneity in setting, analysis and reporting, which inevitably limits the generalizability of the findings.
Opioids are often involved in fatal cases of overdoses [2] . However, the proportion of prisoners having a history of opioid use varies across countries [18] , and may vary over time [19] . Only a few studies have included time trends in the analysis [15, 17, 20, 21] , and so variations across time and setting in post-release mortality have not been investigated sufficiently.
Using this background, we have analysed Norwegian national deaths data following prison release over a 15-year period, investigating risk periods (first week, second week, 3-4 weeks and 2-6 months) over three quinquennia (2000-04, 2005-09, 2010-14) .
We aimed to address three main questions; first, to estimate and compare overdose death rates at time intervals after prison release; secondly, to examine changes in patterns of overdose death rates over calendar time; and thirdly, to identify risk factors for overdose death.
METHODS

Design
This prospective cohort study comprises 105 903 individuals in the Norwegian Prison Registry, contributing 168 772 releases from Norwegian prisons over 15 years (1 January 2000-31 December 2014). Through personal identification numbers, these were linked to data from the Norwegian cause of death registry (1 January 2000-31 December 2014).
Setting
Norway has low rates of imprisonment and high levels of health care, including drug treatment, aiming at rehabilitation. With a national population of 5.2 million, Norway has a prison population of 3700 and in 2014 the prison population rate was 75/100 000 [22] .
Data sources
The Prison Registry serves administrative and statistical purposes, and includes personal data on all individuals imprisoned in Norway, including age, gender, convictions and sentences [23] . The registry captures date of admission and date of release, both for sentences served and time spent on remand. This includes a code describing the release circumstances, which differentiates between 'false releases' (transfers to hospitals, rehabilitation institutions, deaths in prison) and actual prison release.
The Norwegian Death Registry includes complete death certificates reported by medical doctors after examination of the deceased death certificates are collected by the Death Registry at the Norwegian Institute of Public Health, which codes multiple ICD-10 causes of death [24] . The Causes of Death Registry includes information about the underlying cause of death (the disease or injury which initiated the train of morbid events leading directly to death), immediate causes of death (the terminal event or complication present at the moment of death) [25] , information about where the person was found dead and the actual date of death. The coverage and the completeness of the Norwegian Death Registry is high; it comprises all residents and include medical information on more than 98% of all deaths [25] .
Measures
Of the original 105 903 former inmates, we excluded 13 240. The majority of those excluded (12 793) did not have a valid Norwegian identification number and were mainly foreign inmates. Inmates were also excluded in cases of date of death prior to release date, deaths in prison or other institutions and cases where re-entry to prison was coded before the person's release date. The remaining sample comprised 92 663 former prisoners released 153 604 times (Table 1) .
We focused especially on mortality within 6 months following release, therefore data on all former prisoners were right-censored at 6 months. A further 3514 releases were excluded as they were releases in the latter half of 2014, and thus included less than 6 months of follow-up data. The final sample comprised 91 090 former prisoners, released 150 090 times.
The time at risk was defined as: the period between release from prison and death (censored at 6 months), from release to another incarceration (censored at 6 months) or from release throughout 6 months. As the same participant may contribute to multiple 6-month observation periods and at risk after every release, all release-periods are included into the analysis. The time at risk includes only time outside prison; both for individuals with one or repeated incarcerations in the study period, all the time incarcerated was excluded.
Using only the underlying ICD-10 codes of death [24] , we categorized causes of death into five mutually exclusive categories: 'overdose deaths' (F11-F16, F19, F55, X40-X44, X60-X64, X85, Y10-Y14), 'accidents' (V01-V99, W00-W19, W20-W99, X31, X00-X09, X58-X59), 'suicide' (X65-X84, Y87.0) and 'cardiovascular disease/cancer' (C00-C97, I00-I99, G45, G46). All other deaths were categorized as 'other deaths'.
Ethics
The study was approved by the regional Ethics Committee and the Norwegian Correctional Directorate. Data linkage was performed by the Norwegian Institute of Public Health who used anonyms to conduct the analyses.
Statistical analysis
Statistical analyses were performed using Stata (version 14). Descriptive statistics were available for all individuals released from prison who died post-release, and were categorized according to ICD codes. Former inmates whose date of death was the date of release were defined to have died on day 1 (none of these died in prison).
As the number of releases declined annually, weighted mortality rates were calculated to estimate mortality per year of release. Weighted mortality rates were defined as the number of deaths by year of release divided by the number of releases per year and multiplied by 100 (Table 1) .
Crude mortality rates (CMRs) and 95% confidence intervals (CIs) [26] were calculated as number of deaths per 1000 person-years (PY). In order to compare crude mortality rates (CMR), rate ratios (RR) and 95% CIs [27] were examined, with calculation of the ratio between two rates (if there is no difference between two rates, the rate ratio is equal to 1).
Factors associated with overdose death during 6 months post-release were estimated using the Poisson regression model. The coefficients were interpreted in terms of incidence rate ratios (IRR) with 95% confidence intervals. We ran univariate models for all covariates and one multivariate model including all covariates.
Role of the funding source
The funder of the study had no role in study design, data collection, data analysis, data interpretation or writing of the report. The corresponding lead author had full access to all the data in the study and had final responsibility for the decision to submit for publication. Table 1 ). During the 15-year period, men comprised more than 90% of all releases (Table 1) . Annual deaths based on the number of releases the given year, decreased through the 15-year period: in 2000 the weighted mortality rate was 0.84 compared to 0.52 in 2005, 0.43 in 2010 and 0.65 in 2014. Overall, men accounted for more than 90% of deaths, increasing annually during the 15-year period (Table 1) .
During 6 months post-release, the overall all-cause mortality rate was 1245/100 000 PY and the overdose mortality rate was 696/100 000 PY. During the first week post-release, overdose deaths accounted for 85% of all deaths, with accidents accounting for 6% and suicide for 3% (Table 2) . Overdose deaths peaked during the first days post-release, and thereafter declined gradually during the first month post-release (Fig. 1) .
During the second week post-release, the total number of deaths approximately halved (versus first week), with overdose deaths accounting for 68% of all deaths. During weeks 3-4 and months 2-6, overdose death accounted for 62 and 46% of all deaths, respectively. We observed this pattern during all release periods (Supporting information, Table S1 ). A similar pattern was seen with deaths from accidents, but not to the same extent ( Table 2) .
The rate of overdose deaths during the first week postrelease was higher during the 2000-04 quinquennium, compared to 2005-09 and 2010-14 ( Table 3 ). The same differences in overdose deaths according to releasepatterns was also found in week 2, but was less prominent in weeks 2-3 and months 2-6 (Table 3) . The adjusted Poisson regression model showed that, compared to the first week, the incident rate for overdose death was approximately 60% lower (IRR = 0.43; 95% CI = 0.31-0.59) during week 2, almost 80% lower (IRR = 0.22; 95% CI = 0.16-0.31) during weeks 3-4 and almost 90% lower during months 2-6 (Table 4) . (Table 4) .
Women had an increased risk of overdose death during the first 6 months post-release. Duration of incarceration had an inverted U-curve association with risk of overdose death: compared to being incarcerated for 1 month or less, the risk of overdose death was highest for those incarcerated for 3-12 months. Higher number of incarcerations was associated with elevated risk of overdose death post-release (Table 4) .
We also ran Poisson regression models to calculate the potential effect of month of release (January-December) and day of release (Monday-Friday) on overdose mortality during the first week post-release. Neither release month nor release day was associated with overdose mortality (data not shown).
DISCUSSION
The immediate first days post-release have a greatly increased overdose death rate for released prisoners, with Table 2 All-cause and cause-specific mortality rates during different time-periods following release (n = 91 090); crude mortality rates (CMR) per 1000 person-years and 95% confidence interval (CI). the rate of overdose deaths during the first week almost 60% higher compared to the second week, and almost 90% higher than the rate during the 2-6 months following release. During the first week post-release, overdoses accounted for about 85% of all deaths, and the proportion of deaths from overdose versus other causes remained high throughout the 6-month study period. Reductions in death risk were found over calendar time, with the higher rates of overdose death occurring in the early study period. The extremely high overdose mortality rate during the first weeks post-release accords with findings reported elsewhere [10, 14] . A particularly intense peak in overdose mortality was evident during the first few days following release, which supports the findings of Degenhardt et al. [14] and Groot et al. [28] , although more replication studies with large prison release cohorts are still required. Nevertheless, not all studies observe the high level of overdoses after release, with a Swedish registry-based study finding no such peak during the first weeks post-release [4] . Such differences in post-release risk observed from varied settings may derive from different national drug use patterns, e.g. dominated by amphetamine in the Swedish prison population.
First week
More than 50% of all deaths during the 6 months following release were overdose deaths-a finding similar to some studies [29] , but higher than others such as found by Binswanger and colleagues [10] and Håkansson and Table 3 Overdose death at different time-periods and release periods (n = 91 090); crude mortality rates (CMR) per 1000 person-years and 95% confidence interval (CI). colleagues [4] who found approximately a quarter of deaths of released prisoners to be related to drug overdose. The high proportion of overdoses in the immediate period following incarceration might reflect prison settings where released inmates typically have a history of heroin or opioid use, and may also be particularly high in settings where polydrug injection is the common mode of administration, as in the current setting. For several years, Norway has been ranked as one of the European countries with the highest rates of overdose mortality, often explained by high rates of injection drug use and an ageing polydrug-using population [30] [31] [32] . Overall, this means that drug use patterns both in terms of substances consumed as well as mode of administration will be reflected in mortality both in the general populations as well as in prison-release populations. Substantial changes during the 15-year period were identified in our study, with the higher rates of overdose death occurring with those released in the 2000-04 quinquennium, with lower mortality rates among those released in later eras. This finding is similar to other studies conducted in Australia and Scotland, finding a decrease in the standardized mortality rate related to overdose death over time [14, 15, 17, 21] .
There might be several explanations for the observed fall in overdose death over time. The reduction in overdose mortality post-prison parallels the reduction observed in national overdose mortality data and changes over time, with a 40% reduction in drug overdose deaths from 2000 to 2005, followed by more stable annual national overdose mortality rate. For Norway, the reduced risk of overdose across time is due probably to increasing numbers of patients enrolled into the national opioid maintenance programme, with gradually the same access to treatment for prison inmates as those outside prisons, introduced progressively in Norway from 1998 onwards. In Norway, the number of patients in opioid maintenance treatment has increased from 2000 in 2002 to 7000 in 2014 [33, 34] . At the same time, there have been parallel increases in the number of maintenance patients entering the correctional system, annually estimated to approximately 10% of the patient population [33, 35, 36] .
A few studies have investigated the impact of prisonbased opioid maintenance treatment on drug-related death: in a large cohort study of 16 453 prisoners released from prison in New South Wales, Australia, Degenhardt and colleagues found that opioid maintenance treatment provided in prison and post-release reduced mortality independently in the immediate post-release period [14] . Further, in a cohort study including all Scottish prisons, Bird and colleagues found a reduction in the number of drug-related deaths 12 weeks after prison release during the period 1996-2007. The contribution of methadone treatment in the outside community was formulated as a probable explanation of the observed reduction.
An alternative explanation for the reductions in overdose deaths is that the proportion of opioid-dependent prisoners decreased during the observation period. A decrease in the opioid-dependent population entering prisons may be a consequence of the national introduction of opioid maintenance treatment (OMT), as patients enrolled into OMT are less likely to engage in criminal activity [37] , and consequently less likely to be sent to prison. It could also be a consequence that patterns of drug use in the community may shift over time with a smaller proportion of individuals entering prison having a history of opioid use, irrespective of community OMT. In Australia, there has been a marked transition from opioid to methamphetamine use among prison entrants [19] and the same trend could possibly also be found elsewhere. Norway has developed advanced registry databases for the purposes of official statistics and research [38] . The registers are high-quality, nation-wide, continuously updated and have negligible or controllable attrition. Our study includes a nation-wide population of releases with unique identifiers for each individual linked with all deaths obtained from a national cause of death registry. The complete national coverage of the prison registry means that our results are generalizable to the Norwegian prison population as well as to settings where opioid injection is a general characteristic among drug users and prison inmates.
Our study is among the larger studies of prisoner mortality internationally. Due to the high number of deaths captured during the first weeks post-release, we were able to describe all mortality cases based on absolute numbers as well as by statistical estimations.
However, data linkage methods have limitations, including limited demographic and socio-cultural variables. In our study, linkage was only available for individuals provided with Norwegian personal identification numbers, and hence we were not able to follow foreign inmates who did not have a Norwegian identifier. Further, the study cannot distinguish between death rates in drug users released versus other individuals released from prison. Moreover, age was only included as a separate variable for those deceased, and we were thus not able to conduct age-adjusted analysis.
Misclassifications of causes of death may occur in all registry data: it may be that some intentional suicides might be classified as overdose death, causing overestimation of overdose as a cause of death. Conversely, unattended and accident coded deaths may include some misclassified overdose deaths, leading to underestimating the total number of overdose deaths. However, completeness of the Norwegian Death Registry is high, as it includes medical information on more than 98% of all deaths [25] .
Our study has investigated a large sample from one national setting, and our results advance more precise day-by-day understanding of risk of overdose death following prison release. The greater precision about the most critical time-period following release (i.e. to the first few days has) important clinical implications. According to World Health Organization recommendations, comprehensive provision of health-care services is necessary throughout both the period in prison and during subsequent community reintegration [39] . Most importantly, interventions need to be planned in advance and implemented prior to release, in order to address the known high risk of overdose death. Drug-dependent individuals released from prison are doubly vulnerable during the critical transition to civil society. Therefore, collaboration between correctional services, drug treatment services and social services needs to facilitate as safe a release from prison as possible. The practice of continuing approved and effective treatment, such as opioid maintenance treatment [40] as well as provision of naloxone [41] alongside wider harm reduction and social re-integration support in correctional settings is essential in reducing overdose deaths post-release among former inmates.
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